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protein abundances and fT 4 levels were calculated using a 
Pearson correlation.  Results: All subjects developed bio-
chemical thyrotoxicosis, and this effect was reversed within 
the first 4 weeks of follow-up. None of the volunteers noticed 
any subjective symptoms. Levels of 10 proteins involved in 
the coagulation cascade specifically correlated with fT 4 , sup-
porting an influence of thyroid hormone levels on blood co-
agulation even at nonpathological levels.  Conclusions: The 
results suggest that experimental thyrotoxicosis exerts se-
lective and specific thyroxine-induced effects on coagula-
tion markers. Our study design allows assessment of thyroid 
hormone effects on plasma protein levels without secondary 
effects of other diseases or therapies. 
 © 2015 European Thyroid Association
Published by S. Karger AG, Basel 
 Introduction 
 Since the first report more than a century ago, a rela-
tion between hyperthyroidism and hypercoagulation has 
been suspected  [1] . This has been further substantiated in 
a number of recent studies where patients with various 
causes and a variable duration of endogenous hyperthy-
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 Abstract 
 Background: Hyperthyroidism is known to  induce a hyper-
coagulable state. It stimulates plasma levels of procoagula-
tive factors and reduces fibrinolytic activity. So far most of 
the data have been derived from patients with endogenous 
hyperthyroidism with a wide variability in the underlying 
pathogenesis and severity of the disease.  Objectives: In this 
study we experimentally induced thyrotoxicosis in healthy 
volunteers to explore the effects of thyroxine excess on the 
plasma proteome. Using a shotgun proteomics approach, 
the abundance of plasma proteins was monitored before, 
during and after thyrotoxicosis.  Methods: Sixteen healthy 
male subjects were sampled at baseline, 4 and 8 weeks un-
der 250 μg/day thyroxine p.o., as well as 4 and 8 weeks after 
stopping the application. Plasma proteins were analyzed
after depletion of 6 high-abundance proteins (MARS6) by 
LC-ESI-MS/MS mass spectrometry. Mass spectrometric raw 
data were processed using a label-free, intensity-based 
workflow. Subsequently, the linear dependence between 
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roidism have been investigated as to their coagulation 
system under basal conditions and following treatment to 
the euthyroid state. These data show that thyrotoxicosis 
stimulates several procoagulatory and fibrinolytic factors, 
namely factor VIII (FVIII), factor IX (FIX) and von Wil-
lebrand factor. In parallel, reduced fibrinolytic activity 
based on an increased level of plasminogen activator in-
hibitor I (PAI-I) has been reported  [2] . Interestingly, clot 
lysis time decreased during normalizing thyroid func-
tion. A recent study applying confocal and electron mi-
croscopy to evaluate clot structure supported more com-
pact clots in the hyperthyroid state  [3] . Despite these clear 
effects in many published reports included in a recent 
large systematic meta-analysis, the authors concluded 
that ‘the majority of these studies suffer of major meth-
odological flaws which leaves the net effect of thyroid 
hormone excess on the haemostatic system unclear’  [2] . 
Particularly, the mechanism mediating the influence of 
thyroid hormones on the coagulation system has not 
been elucidated yet. 
 Due to the effect of thyroid hormones on several fibri-
nolytic and coagulation parameters, plasma proteins have 
been seen as important factors in several clinical studies 
 [2] . However, the impact of thyroid hormone levels on 
the total plasma protein pattern representing classical 
plasma proteins produced in the liver, as well as leakage 
proteins from tissues and organs as well as cytokines, is 
also of general interest  [4] . Since blood is an easily acces-
sible biofluid that reflects the systemic health status of a 
patient and is routinely collected for clinical diagnostics, 
plasma is a prime source for the identification of bio-
marker candidates with diagnostic and prognostic value. 
With the maturing of mass spectrometry techniques and 
data analysis workflows, proteomics can now be used as 
a tool to disclose biomarker candidates in plasma by per-
forming nontargeted comprehensive analysis of plasma-
derived peptides and proteins. After depletion of highly 
abundant proteins, hundreds of proteins can be identified 
and quantified.
 The data of the studies on impact of thyroid hor-
mones on plasma composition described above indicate 
that the clinical situation may be obscured by associated 
factors not well controlled so far. The investigation pre-
sented here tried to avoid these pitfalls by profiling pure 
thyroxine-related effects during experimentally in-
duced thyrotoxicosis in otherwise healthy volunteers. 
By using an unsupervised proteomic approach, we fur-
ther tried to avoid any preselection of factors and in-
stead aimed at an unbiased view of thyroid hormone-
mediated effects.
 Material and Methods 
 Study Design and Sampling 
 Sixteen healthy male volunteers were prescribed 0.25 mg of
levothyroxine per day with blood withdrawal at baseline, 4 and 8 
weeks under T 4 administration, and 4 and 8 weeks after stopping 
the application. Subjects were aged 27.75 ± 3.9 years and had a BMI 
of 21–30. For the different analysis methods, serum and EDTA 
plasma were stored at –80  °  C. This work was approved by the local 
ethics committee and written informed consent was obtained from 
all participants.
 Assays 
 Serum levels of thyrotropin [i.e. thyroid-stimulating hormone 
(TSH)], free triiodothyronine (fT 3 ) and free thyroxine (fT 4 ) were 
measured using immunoassays. Sex hormone-binding globulin 
(SHBG) as well as FIX and FXIII subunit B concentrations were de-
termined in EDTA plasma using a chemiluminescent enzyme im-
munoassay (detailed description in suppl. methods, for all online 
suppl. material, see www.karger.com/doi/10.1159/000381769). 
 Depletion of High-Abundance Proteins and Sample 
Preparation of EDTA Plasma 
 Depletion of the 6 high-abundance proteins was performed via 
multiaffinity chromatography (MARS6-human; Agilent Tech-
nologies, Waldbronn, Germany) according to the manufacturer’s 
protocol. The nonbound fraction containing lower-abundance 
plasma proteins was precipitated with trichloroacetic acid (final 
concentration 15%), and the pellet was resuspended in 100 μl of 
UT-buffer (8  M urea and 2  M thiourea). Protein concentrations 
were determined using a Bradford Assay (Bio-Rad Laboratories, 
Munich, Germany) with bovine serum albumin as the standard 
protein.
 Protein Identification and Quantification 
 Mass spectrometric analysis of tryptic peptide lysates was per-
formed on an Orbitrap Velos Mass Spectrometer (Thermo Elec-
tron, Bremen, Germany) after prefractionation by RP-HPLC as 
described  [5] . The obtained raw data were analyzed using the
Refiner MS software version 7.6.6 (GeneData, Basel, Switzerland). 
For further details of sample preparation, protein identification 
and quantification, see the online supplementary methods.
 Results 
 Subject Characteristics 
 After 4 weeks of treatment with levothyroxine (time 
point 2 = T2), the mean fT 4 levels rose from 13.24 ± 0.35 
pmol/l (baseline = T1) to 28.6 ± 1.63 pmol/l, associated 
with an increase in the fT 3 levels from 5.26 ± 0.13 to 9.19 
± 0.5 pmol/l. TSH was 2.1 ± 0.25 mU/l at baseline, drop-
ping to 0.017 ± 0.007 mU/l after 4 weeks and staying at 
this low level (0.007 ± 0.002 mU/l) after 8 weeks (T3) as 
well. All thyroid hormone levels returned to pretreatment 
levels after discontinuation of levothyroxine exposure 
(T4) and stabilized (T5;  fig. 1 ).
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 Proteomic Profiling of Plasma Proteins  
 Mass spectrometric analysis of all 80 plasma samples 
was performed in single LC-MS/MS runs. In total, 2,374 
unique peptides representing 497 human proteins were 
identified. Only proteins identified in more than 60%
of all samples (n = 439) were considered for quantifi-
cation.
 Among those proteins, SHBG could be quantified, a 
commonly used marker of thyrotoxicosis. In order to 
prove the sensitivity and validity of the proteomic ap-
proach, we first compared these LC-MS/MS-determined 
changes in SHBG protein levels due to levothyroxine 
treatment to the direct measurement of the protein using 
a routinely applied, highly sensitive ELISA ( fig. 2 ). Both 
ELISA and LC-MS/MS measurement displayed very sim-
ilar patterns, but the former seemed to be more sensitive.
 Correlation of Plasma Proteins with fT 4 Levels 
 The fT 4 levels and the protein abundance of the 439 
proteins included in the analysis were correlated accord-
ing to Pearson’s correlation ,  revealing a large subset of 
proteins with a correlation coefficient | r |  ≥ 0.8. Func-
tional categorization of correlated proteins for canoni-
cal pathways revealed the coagulation cascade with a 
high number of assigned proteins. Of the 35 proteins 
assigned to the coagulation cascade, 24 proteins (almost 
70%) were detected by our LC-MS/MS analysis (suppl. 
table S1). Out of these 24 proteins, 10 showed a signifi-
cant correlation (| r |  ≥ 0.8) with plasma fT 4 levels ( fig. 3 ). 
 The majority of the coagulation proteins displayed a 
positive correlation. The strongest linear dependence was 
observed between coagulation FXIII subunit B and fT 4 
with a coefficient  r = 0.991, revealing a strong increase
in protein abundance caused by T 4 administration. The 
FXIII subunit B protein level returned to baseline quickly 
after discontinuation of T 4 . Moreover, FIX could be found 
with an  r = 0.938, whereas the correlation and signifi-
cance of FV ( r = 0.816), FII ( r = 0.813) and FXI ( r = 0.811) 
were slightly lower but showed the same tendency. Exem-
plarily, conventional ELISAs were performed for FIX and 
FXIII ( fig. 4 ; online suppl. fig. S1), which yielded the same 
pattern and thus confirmed the data of the LC-MS/MS 
measurements. The other detected coagulation factors 
(FVII, FX, FXII, FXIII subunit A) showed no significant 
correlation with fT 4 . Other proteins with strong positive 
correlation included PAI-III, antithrombin III and 
 α 2 -antiplasmin, all belonging to the serpin peptidase in-
hibitor family. In contrast, plasminogen was the only pro-
tein which displayed a significant negative correlation 
( r = –0.976;  fig. 5 ). 
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 Fig. 1. Kinetics of thyroid hormones fT 4 , 
fT 3 and TSH levels after oral administra-
tion of 0.25 mg of levothyroxine per day. 
Hormone levels of each time point are 
shown as means ± SD. Horizontal lines in-
dicate the maximum value of the reference 
interval for the specific TH (minimum val-
ue for TSH, respectively). 
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 Fig. 2. Relative change of SHBG. Protein levels of each time point 
are normalized to those at baseline immediately before levothyrox-
ine administration (mean ± SEM). Black line: ELISA measure-
ments; dashed line: proteomics data. 
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 Discussion 
 The model of experimentally induced thyrotoxicosis 
has a number of advantages compared to endogenous hy-
perthyroidism as the extent and duration of thyroxine ex-
cess is defined. By treating healthy volunteers, a potential 
impact of comorbidity on the plasma proteome was ex-
cluded. 
 The fT 4 levels reached in the current intervention 
study were all within the range that will be left untreated 
in clinical practice. Nevertheless, SHBG displayed elevat-
ed levels correlating with increased free T 4 levels reveal-
 Fig. 3. Schematic view of the coagulation cascade. Colored boxes 
highlight proteins with  r  ≥ 0.9 (dark red);  r  ≥ 0.8 (light red); r  ≤ –0.9 
(green). Gray boxes: proteins were covered by the analysis, but
displayed no significant correlation (0.8  ≥  r  ≥ –0.8). A2M = α 2 -
Macroglobulin; F2 = coagulation factor II; FG = fibrinogen;
KLKB1a = plasma kallikrein; PLG = plasminogen; SERPINA1 = 
α 1 -antitrypsin; SERPINA5 = protein C inhibitor; SERPINC = an-
tithrombin III; SERPIND1 = heparin cofactor II; TFPI = tissue fac-
tor pathway inhibitor; THBD = thrombomodulin; TPA = tissue 
plasminogen activator; UPA = urokinase plasminogen activator; 
VWF = von Willebrand factor. 
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ing toxic side effects even already at slightly increased thy-
roid hormone levels. 
 In contrast to many former studies targeting the effect 
of thyroid hormone imbalances on specific proteins such 
as those involved in coagulation and fibrinolysis  [2] , as a 
proof-of-principle study we aimed at a comprehensive 
monitoring of alterations in plasma protein levels inde-
pendent of their biological function. Thus, a large num-
ber of proteins were quantified across all samples, includ-
ing SHBG. This known marker protein exhibited compa-
rable levels among the proteomics data and the ELISA 
measurements, confirming the technical feasibility of the 
shotgun proteomic approach.
 Not surprisingly, the correlation analysis revealed a di-
rect impact of thyroid hormones on proteins involved in 
the clotting cascade. Specifically, the procoagulatory fac-
tors XIII subunit B, II, XI and IX increased at higher fT 4 
levels. Concomitantly, plasminogen which is the main en-
zyme promoting fibrinolysis in its activated form plasmin 
was decreased. This indicates that increased fT 4 levels may 
induce a hypercoagulable state by directly interfering with 
the synthesis of clotting factors in the liver. Indeed, it was 
recently demonstrated by the MEGA study that patients 
with increased fT 4 levels possess an up to twofold higher 
risk for venous thrombosis and/or pulmonary embolism 
 [6] . The effect of levothyroxine exposure on coagulation 
and fibrinolysis has already been addressed specifically in 
a controlled randomized crossover study in healthy vol-
unteers  [7] . Upon increase in free thyroxine, increased 
levels of procoagulant coagulation factors including FIX 
were observed, an observation that was confirmed in our 
study. However, not all details were matching. For exam-
ple, in contrast to the data of van Zaane et al.  [7] , levels of 
von Willebrand factor did not change in our study. The 
differences observed for specific coagulation factors might 
reflect different stages of thyrotoxicosis and/or different 
properties of the assay methods used. 
 Additionally, the lower plasminogen levels detected in 
our proteomic study might indicate a hypofibrinolytic 
state. A large meta-analysis by Stuijver et al. [2] demon-
strated elevated PAI-I levels in patients with hyperthy-
roidism, which also points towards hypofibrinolysis. 
PAI-I was not detected in our proteomic approach, but 
downregulation of plasminogen itself may also contrib-
ute to the hypofibrinolytic state, and blockade of fibrino-
lysis by increased PAI-I levels is not the only mechanism.
 However, global plasma protein profiling disclosed pro-
tein alterations besides the typical proteins studied for the 
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 Fig. 4. Evaluation of LC-MS/MS results for 
FIX and FXIII subunit B by ELISA. Protein 
levels of each time point are normalized to 
those at baseline immediately before levo-
thyroxine administration (mean ± SEM). 
Black line: ELISA measurements; dashed 
line: proteomics data. 
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 Fig. 5. Relative change to baseline of proteins involved in the co-
agulation cascade. Lines indicate the correlation between protein 
abundance and fT 4 level:  r  ≥ 0.8 (black) and r  ≤ –0.8 (dark gray). 
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evaluation of coagulation and fibrinolysis  [7] . Thus, an-
other interesting finding was the increase in serpin A5 
(protein C inhibitor), which is a potent inhibitor of acti-
vated protein C  [8, 9] . Activated protein C inhibits clot 
formation. An increase in serpin A5 lowers the inhibition 
of clot formation by activated protein C, further contribut-
ing to the prohemostatic role of elevated fT 4 levels. Fur-
thermore, several anticoagulatory factors such as antitryp-
sin, antithrombin III and α 2 -antiplasmin were also in-
creased and may mirror an anticoagulatory compensatory 
mechanism, which is typical for the coagulation cascade.
 Overall, this study provides new insights into the as-
sociation of circulating plasma fT 4 levels with a large sub-
set of plasma proteins not restricted to proteins involved 
in coagulation and fibrinolysis, but also other protein 
classes which have to be analyzed in detail. Our study dif-
fers substantially from endogenous hyperthyroidism be-
cause it is limited to the direct effects of thyroxine ad-
dition and displays different dynamics and secretion
patterns of thyroid hormones. Thus, our experimental 
approach has clear advantages for capturing pure thyroid 
hormone-dependent effects.
 Conclusions 
 The results of this study suggest that experimental
thyrotoxicosis exerts selective and specific thyroxine-
induced effects on coagulation markers. The increase in 
procoagulant clotting factors, a decrease of fibrinolytic 
enzymes and an enhanced inhibition of the protein C 
pathway may contribute to the hypercoagulable state in 
thyrotoxicosis. Furthermore, the study design presented 
allows assessment of thyroid hormone effects such as 
those on the coagulation system but also on the whole set 
of plasma proteins without interference of other diseases 
or therapies.
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